Amro Albanna (00:03): Great. Jeff, how you doing today? Jeff Ramson (00:05): I'm good, Amro. How are you doing? Amro Albanna (00:06): Wonderful. Thanks for doing this again, and thanks, everyone, for joining us. This is

Amro Albanna (00:03):

Great. Jeff, how you doing today?

Jeff Ramson (00:05):

I'm good, Amro. How are you doing?

Amro Albanna (00:06):

Wonderful. Thanks for doing this again, and thanks, everyone, for joining

us. This is a great opportunity for us to engage with our stakeholders, share updates, and answer questions. We've been receiving excellent

questions from all over the world, and Jeff and I want to make sure we address as many of them as possible, within what's publicly available.

So, Jeff, maybe I'll start with you.

Jeff Ramson (00:34):

Amro Albanna (00:35):

First of all, how do you feel, maybe before we go there, Jeff, just

because not everybody maybe joined us last time, maybe you can do a quick intro-

Jeff Ramson (00:45):

Amro Albanna (00:46):

... on yourself, your role, how long you've been involved with us,

and we can go from there.

Jeff Ramson (00:51):

Happy to do that. I'm Jeff Ramson, CEO of PCG Advisory, and I've

known Amro for quite some time. As I mentioned last week, I was an early investor in Aditxt before it went public and have worked closely

with Amro over the years. We've recently reconnected, and this is an incredibly exciting time for Aditxt-challenging, but

very exciting. We see the opportunity as asymmetrical, and as both an investor and advisor to Amro, as well as a strong advocate for the

company, I'm happy to join each of these weekly calls.

Our goal here right now is to try to create a more transparent, authentic

kind of communication than you typically see with small microcap public companies. And I give Amro a lot of credit for his efforts and,

and frankly, his success in those communications. Amro, as we discussed, there's a, there's a few common themes that we get in our questions

and there's so really kind of a, we can- consolidate those into main topics, but I know you had quite a busy week, and you might want

to just do a kind of quick recap on some of the events, if that's a good place to start.

Amro Albanna (02:09):

Yeah, no, no. I mean, Jeff, look, you characterize it well, and I'm

looking at the screen here, we have about 57 attendees, I'm sure that's, you know, part of that is our own team, which is wonderful, our

own stakeholders. But like you said, I mean, were just starting these fireside chats, and my hope and my goal is for us to have thousands

in the future. We, we need to go beyond just the filings that we do and what a public company has to do beyond the 10-Ks, beyond the 10-Qs,

beyond the 8-Ks. And - it's really important for us to make sure that our stakeholders and our current shareholders understand what's

going on. So, I have a list of questions here that came from Peter.

Peter, in case you're listening, we get your questions. We truly appreciate

your thoughtfulness, and that's really what we want to accomplish. We had the fireside chat last week, actually it was last Monday with

Saundra and Dr. Drew. We received really, really positive feedback because it really begins to show why Evofem is an important company

for us, women's health, how we're looking at Evofem as a foundation for women's health with the product they have right now, and the future

vision that we see building on Evofem, starting with their team.

So, with that, maybe we can start with NASDAQ. I know that's a question

that's been coming over and over and over again. And look, so, you know, I want to be very clear with NASDAQ compliance as far as the

bid price, and of course with NASDAQ compliance, it, it involves more than just the bid price. We have stockholders equity, we have the

number of floats or the number of shares on the float. But right now, the biggest concern has been, and understandably so, the, the price

So let me be very clear as far as where we are, where we believe we

are when it comes to the bid price. So before October 2nd, that's the date we did our reverse split, we were below a dollar for 30 consecutive

days, and we received a NASDAQ letter, which we published on an 8-K, I think it was October 2nd, October 3rd, whenever I think we received

the letter, it was October 3rd.

Amro Albanna (04:39):

On October 2nd, we had a reverse split, right- Prior to October 2nd,

we had, we were below a dollar for 30 consecutive days. We received a letter from NASDAQ and we 8-K'd that letter, right, that,

that, that correspondence. When we did our reverse split on October 2nd, our stock went above a dollar, and we, we, we maintained the

share price was above one dollar for 10 consecutive days, which are the number of days required to, to, to, to re-comply with the bid

price. So if a company goes below 30 days below one dollar for 30 days, NASDAQ will give the company, which they did for us six months

until April, 2025, to comply with the bid price by trading above a dollar for 10 days, which we did by doing the reverse split.

So right now, we believe we are in compliance with the bid price, but

our stock has been trading below a dollar again, but it's has not been 30 days, it's been roughly 12, 13 days. And people can go online

and see historically what that is. So we believe we're in compliance with the bid price based on the letter that we, based on the previous

letter. We did not get confirmation from NASDAQ to be clear, but we be, you know, we traded above a dollar for 10 to consecutive days,

so we believe we're, we're back in compliance. Of course, if the stock trades below a dollar for 30 consecutive days, again, we expect

a letter, we expect another six months. And that's, that's where we are. Jeff, is that clear? Or is this something that we need to clarify?

Jeff Ramson (06:21):

I think that's clear. I, I think that made that, that makes sense.

So everyone can understand, like, what the current status is and what your timeline is in the event that you've stayed below a dollar

for the 30 days. I think that that makes sense.

Amro Albanna (06:33):

Yeah, and I think, you know, one of the things that I saw in some of

the questions, I think there was almost a concern about imminent delisting, like, you know, this week, next week. That is not, certainly,

that is not our understanding, and it's not something that we are concerned about as far as, you know, imminent delisting from NASDAQ.

That is not what we're dealing with. Again, we're... You know, as, as we stand right now, we believe if we trade below a dollar for another

total of 30 consecutive days, we'll have another six months. But that's, that's our understanding based on the last letter we received.

Jeff Ramson (07:05):

Right. You know, this kind of really dovetails into the other part

of the conversation, which is you've got acquisitions on the table, they require capital. I think that you know, it's a good idea to continue

to address how you plan to obtain that capital, um, because clearly, that, that makes a big difference to how the stock will trade and

Amro Albanna (07:29):

Jeff Ramson (07:29):

Maybe this is a good time to talk a bit about that.

Amro Albanna (07:31):

Definitely. So that's another important point. Look, you know, obviously,

there's so much happening with the company. A lot of... I mean, it's pretty dynamic. There are acquisitions, there are existing subsidiaries

that we're working on. You know, there is capital market related activities. There is some, other activities that we're dealing with.

But for our, for our shareholders and our stakeholders, I think the best way to organize it is this. We have the business component. We

ultimately have to build a business. We have to make sure that we advance and accelerate our innovations and get it to the market. Otherwise,

you know, what are we doing this for? That's number one.

Number two, we're working diligently, and we'll get into that into

a bit more details to actually clean up some of the overhang that we have as a company, as a microcap company, as a, as a young company,

we want to make sure that we address our debt, preferred, and that's part of our plan that we're working on. And then number three, obviously

the stock, the capital market component. And that's how we will summarize it on this call and moving forward. So starting with the business,

we have two key acquisitions that we've been working on. And, people need to realize that Evofem is a company that we've been associated

with in one form or another for the last three, three and a half years. We've known them for a long time. We've known the company, the

company's working on pretty significant innovations in our view.

And they have one program that's fully funded by the US Air Force.

They have another program that's commercial and being, and is, is licensed with another licensee. And then the 1801 program. You saw the

press release that Appili put out, which was very encouraging that they reached an alignment with the FDA as far as their plan moving

forward. And depending on the next six months or eight months, we'll see what the results of that that plan will look like. But that was

a really positive milestone. With Evofem, we've all heard from Saundra last time. She certainly articulates her business and women's health

in general very well. You know, they have a product, it's a selling product. They roughly have about $18 million in revenues. We believe

we can expand on that foundation.

So the question for us isn't whether Appili and Evofem are very strategic